常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
22.95/40.70
|
|
企业价值
925.23B
|
| 资产负债 |
|
每股账面净值
29.71
|
| 现金流量 |
|
现金流量率
0.02
|
| 损益表 |
|
收益
65.18B
|
|
每股收益
35.92
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltzand Olumiant for immunology. |

1,008.39 
